Journal of Neuroscience, Vol 4, 2906-2911, Copyright © 1984 by Society for Neuroscience
Binding of the nicotinic cholinergic antagonist, dihydro-beta- erythroidine, to rat brain tissue
M Williams and JL Robinson
The nicotinic cholinergic antagonist, dihydro-beta-erythroidine, binds to
two sites in rat cortical membranes with dissociation constants of 4 and 22
nM and respective apparent Bmax values of 52 and 164 fmol/mg of protein.
Binding to the higher affinity site, defined by the use of 2 nM
[3H]dihydro-beta-erythroidine, was saturable, reversible, and susceptible
to protein denaturation. Binding was highest in the thalamus and lowest in
the spinal cord and showed preferential enrichment in a synaptosomal
subfraction of rat brain. Nicotine displaced [3H]dihydro-beta-erythroidine
in a stereospecific manner, the (-)-isomer being approximately 6 times more
potent than the (+)-isomer. The alkaloid nicotinic agonists, cytisine and
lobeline, were potent inhibitors of binding, while acetylcholine in the
presence of the cholinesterase inhibitor di-isopropylfluorophosphate was
equipotent with (+)-nicotine. Binding was also inhibited by the muscarinic
ligands, arecoline, atropine, and oxotremorine. The nicotinic antagonists
mecamylamine, hexamethonium, and pempidine were essentially inactive in
displacing [3H]dihydro-beta-erythroidine. These findings indicate that
dihydro-beta-erythroidine binds to a nicotinic recognition site in rat
brain which is neuromuscular, rather than ganglionic, in nature and that
such binding is similar in several respects to that seen with nicotinic
agonists. Whether such binding is to a nicotinic, as opposed to nicotinic
cholinergic, recognition site or to a "common" nicotinic/muscarinic site is
an issue that requires further study.